Literature DB >> 24423651

Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment.

Jayoung Kim1, Samantha Morley2, Minh Le3, Denis Bedoret4, Dale T Umetsu4, Dolores Di Vizio1, Michael R Freeman1.   

Abstract

The gene encoding the cytoskeletal regulator DIAPH3 is lost at high frequency in metastatic prostate cancer, and DIAPH3 silencing evokes a transition to an amoeboid tumor phenotype in multiple cell backgrounds. This amoeboid transformation is accompanied by increased tumor cell migration, invasion, and metastasis. DIAPH3 silencing also promotes the formation of atypically large (> 1 μm) membrane blebs that can be shed as extracellular vesicles (EV) containing bioactive cargo. Whether loss of DIAPH3 also stimulates the release of nano-sized EV (e.g., exosomes) is not established. Here we examined the mechanism of release and potential biological functions of EV shed from DIAPH3-silenced and other prostate cancer cells. We observed that stimulation of LNCaP cells with the prostate stroma-derived growth factor heparin-binding EGF-like growth factor (HB-EGF), combined with p38MAPK inhibition caused EV shedding, a process mediated by ERK1/2 hyperactivation. DIAPH3 silencing in DU145 cells also increased rates of EV production. EV isolated from DIAPH3-silenced cells activated AKT1 and androgen signaling, increased proliferation of recipient tumor cells, and suppressed proliferation of human macrophages and peripheral blood mononuclear cells. DU145 EV contained miR-125a, which suppressed AKT1 expression and proliferation in recipient human peripheral blood mononuclear cells and macrophages. Our findings suggest that EV produced as a result of DIAPH3 loss or growth factor stimulation may condition the tumor microenvironment through multiple mechanisms, including the proliferation of cancer cells and suppression of tumor-infiltrating immune cells.

Entities:  

Keywords:  AKT1; EMT; amoeboid; extracellular vesicles; immune cells; miR125a; microvesicles; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24423651      PMCID: PMC3979818          DOI: 10.4161/cbt.27627

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  65 in total

Review 1.  Extracellular vesicles--vehicles that spread cancer genes.

Authors:  Janusz Rak; Abhijit Guha
Journal:  Bioessays       Date:  2012-03-22       Impact factor: 4.345

2.  Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.

Authors:  Jayoung Kim; Rosalyn M Adam; Michael R Freeman
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

3.  ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.

Authors:  Li-Jie Xiao; Ping Lin; Feng Lin; Xin Liu; Wei Qin; Hai-Feng Zou; Liang Guo; Wei Liu; Shu-Juan Wang; Xiao-Guang Yu
Journal:  Int J Oncol       Date:  2011-12-23       Impact factor: 5.650

Review 4.  Roles of microRNAs and other non-coding RNAs in breast cancer metastasis.

Authors:  Scott Valastyan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-03       Impact factor: 2.673

Review 5.  Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'.

Authors:  Tae Hoon Lee; Esterina D'Asti; Nathalie Magnus; Khalid Al-Nedawi; Brian Meehan; Janusz Rak
Journal:  Semin Immunopathol       Date:  2011-02-12       Impact factor: 9.623

Review 6.  Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.

Authors:  Crislyn D'Souza-Schorey; James W Clancy
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 7.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

8.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

9.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

Review 10.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery.

Authors:  Susan M van Dommelen; Pieter Vader; Samira Lakhal; S A A Kooijmans; Wouter W van Solinge; Matthew J A Wood; Raymond M Schiffelers
Journal:  J Control Release       Date:  2011-11-25       Impact factor: 9.776

View more
  38 in total

1.  Coordinated Regulation of Intracellular Fascin Distribution Governs Tumor Microvesicle Release and Invasive Cell Capacity.

Authors:  James W Clancy; Christopher J Tricarico; Daniel R Marous; Crislyn D'Souza-Schorey
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

2.  Biogenesis of Extracellular Vesicles.

Authors:  Taeyoung Kang; Ishara Atukorala; Suresh Mathivanan
Journal:  Subcell Biochem       Date:  2021

3.  Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells.

Authors:  Jae Hun Jung; Min Young Lee; Do-Young Choi; Jae Won Lee; Sungyong You; Kye Young Lee; Jayoung Kim; Kwang Pyo Kim
Journal:  Proteomics       Date:  2015-01-16       Impact factor: 3.984

Review 4.  Epigenetic control of the tumor microenvironment.

Authors:  David L Marks; Rachel Lo Olson; Martin E Fernandez-Zapico
Journal:  Epigenomics       Date:  2016-10-04       Impact factor: 4.778

Review 5.  The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers.

Authors:  H Jin; Y Wu; X Tan
Journal:  Clin Transl Oncol       Date:  2017-02-06       Impact factor: 3.405

Review 6.  The biology of extracellular microvesicles.

Authors:  Alanna E Sedgwick; Crislyn D'Souza-Schorey
Journal:  Traffic       Date:  2018-03-25       Impact factor: 6.215

7.  Secretion of Mutant DNA and mRNA by the Exosomes of Breast Cancer Cells.

Authors:  Olga E Andreeva; Yuri Y Shchegolev; Alexander M Scherbakov; Ekaterina I Mikhaevich; Danila V Sorokin; Margarita V Gudkova; Irina V Bure; Ekaterina B Kuznetsova; Dmitry S Mikhaylenko; Marina V Nemtsova; Dmitry V Bagrov; Mikhail A Krasil'nikov
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

Review 8.  Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.

Authors:  Yan Hu; Yajie Sun; Chao Wan; Xiaomeng Dai; Shuhui Wu; Pui-Chi Lo; Jing Huang; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-04-13       Impact factor: 10.435

9.  Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes.

Authors:  Samantha Morley; Sungyong You; Sara Pollan; Jiyoung Choi; Bo Zhou; Martin H Hager; Kenneth Steadman; Cristiana Spinelli; Kavitha Rajendran; Arkadiusz Gertych; Jayoung Kim; Rosalyn M Adam; Wei Yang; Ramaswamy Krishnan; Beatrice S Knudsen; Dolores Di Vizio; Michael R Freeman
Journal:  Sci Rep       Date:  2015-07-16       Impact factor: 4.379

10.  Potential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication Consortium.

Authors:  Peter J Quesenberry; Jason Aliotta; Giovanni Camussi; Asim B Abdel-Mageed; Sicheng Wen; Laura Goldberg; Huang-Ge Zhang; Ciro Tetta; Jeffrey Franklin; Robert J Coffey; Kirsty Danielson; Vinita Subramanya; Ionita Ghiran; Saumya Das; Clark C Chen; Kae M Pusic; Aya D Pusic; Devasis Chatterjee; Richard P Kraig; Leonora Balaj; Mark Dooner
Journal:  J Extracell Vesicles       Date:  2015-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.